S-23 (drug)
From Wikipedia, the free encyclopedia
 | |
|---|---|
| Systematic (IUPAC) name | |
| (2S)-N-(4-cyano-3-trifluoromethylphenyl)-3-(3-fluoro-4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide | |
| Clinical data | |
| Legal status | Investigational new drug |
| Identifiers | |
| ATC code | ? |
| PubChem | CID 24892822 |
| Chemical data | |
| Formula | C18H13ClF4N2O3 |
| Mol. mass | 416.753 g/mol |
| SMILES
| |
 (what is this?) (verify) | |
S-23 is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc as a potential male hormonal contraceptive. It binds to the androgen receptor more strongly than older drugs such as andarine with a Ki of 1.7nM, and in animal studies it showed both a good ratio of anabolic to androgenic effects, and dose-dependent suppression of spermatogenesis with spontaneous recovery after cessation of treatment.[1][2]
References
- ↑ Marhefka CA, Gao W, Chung K, Kim J, He Y, Yin D, Bohl C, Dalton JT, Miller DD. Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. Journal of Medicinal Chemistry. 2004 Feb 12;47(4):993-8. PMID 14761201
- ↑ Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT. Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology. 2009 Jan;150(1):385-95. doi:10.1210/en.2008-0674 PMID 18772237
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.